New antibody IBI311 takes on steroids in Head-to-Head trial for thyroid eye disease

NCT ID NCT07152340

Recruiting now Disease control Sponsor: Shanghai Changzheng Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tests whether a new drug called IBI311 works better than standard steroid therapy for people with active moderate to severe thyroid eye disease. 64 participants will receive either IBI311 or steroids, and researchers will measure improvements in eye bulging, inflammation, and double vision. The goal is to find a more effective and safer first treatment option.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IBI311 (a lab-made antibody that blocks IGF-1 receptors) and glucocorticoids (methylprednisolone, a steroid hormone)
What this could lead to: If successful, this study could show that IBI311 is a safer or more effective first treatment for thyroid eye disease than standard steroid therapy.
What could go wrong: This is a small, early-phase 4 trial with only 64 participants, so results may not apply to everyone. IBI311 may cause side effects like any antibody drug, and it's not yet proven better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for THYROID ASSOCIATED OPHTHALMOPATHIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endocrine exophthalmos Graves Ophthalmopathy growth delay due to insulin-like growth factor I resistance

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

THYROID ASSOCIATED OPHTHALMOPATHIES

Contacts and locations

Locations

Shanghai Changzheng Hospital
RECRUITING

Changhua, Shanghai Municipality, 200003, China
Shanghai Changzheng Hospital
NOT_YET_RECRUITING

Shanghai, Shanghai Municipality, 200003, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.